Table of Content

1 Biological Vaccines Adjuvants Market Overview
1.1 Product Overview and Scope of Biological Vaccines Adjuvants
1.2 Biological Vaccines Adjuvants Segment by Type
1.2.1 Global Biological Vaccines Adjuvants Market Value Comparison by Type (2024-2034)
1.2.2 Aluminum Adjuvant
1.2.3 Emulsions Adjuvant
1.2.4 Others
1.3 Biological Vaccines Adjuvants Segment by Application
1.3.1 Global Biological Vaccines Adjuvants Market Value by Application: (2024-2034)
1.3.2 Human Vaccine
1.3.3 Veterinary Vaccine
1.4 Global Biological Vaccines Adjuvants Market Size Estimates and Forecasts
1.4.1 Global Biological Vaccines Adjuvants Revenue 2018-2029
1.4.2 Global Biological Vaccines Adjuvants Sales 2018-2029
1.4.3 Global Biological Vaccines Adjuvants Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Biological Vaccines Adjuvants Market Competition by Manufacturers
2.1 Global Biological Vaccines Adjuvants Sales Market Share by Manufacturers (2018-2024)
2.2 Global Biological Vaccines Adjuvants Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Biological Vaccines Adjuvants Average Price by Manufacturers (2018-2024)
2.4 Global Biological Vaccines Adjuvants Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Biological Vaccines Adjuvants, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biological Vaccines Adjuvants, Product Type & Application
2.7 Biological Vaccines Adjuvants Market Competitive Situation and Trends
2.7.1 Biological Vaccines Adjuvants Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biological Vaccines Adjuvants Players Market Share by Revenue
2.7.3 Global Biological Vaccines Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biological Vaccines Adjuvants Retrospective Market Scenario by Region
3.1 Global Biological Vaccines Adjuvants Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Biological Vaccines Adjuvants Global Biological Vaccines Adjuvants Sales by Region: 2018-2029
3.2.1 Global Biological Vaccines Adjuvants Sales by Region: 2018-2024
3.2.2 Global Biological Vaccines Adjuvants Sales by Region: 2024-2029
3.3 Global Biological Vaccines Adjuvants Global Biological Vaccines Adjuvants Revenue by Region: 2018-2029
3.3.1 Global Biological Vaccines Adjuvants Revenue by Region: 2018-2024
3.3.2 Global Biological Vaccines Adjuvants Revenue by Region: 2024-2029
3.4 North America Biological Vaccines Adjuvants Market Facts & Figures by Country
3.4.1 North America Biological Vaccines Adjuvants Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Biological Vaccines Adjuvants Sales by Country (2018-2029)
3.4.3 North America Biological Vaccines Adjuvants Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biological Vaccines Adjuvants Market Facts & Figures by Country
3.5.1 Europe Biological Vaccines Adjuvants Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Biological Vaccines Adjuvants Sales by Country (2018-2029)
3.5.3 Europe Biological Vaccines Adjuvants Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biological Vaccines Adjuvants Market Facts & Figures by Country
3.6.1 Asia Pacific Biological Vaccines Adjuvants Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Biological Vaccines Adjuvants Sales by Country (2018-2029)
3.6.3 Asia Pacific Biological Vaccines Adjuvants Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biological Vaccines Adjuvants Market Facts & Figures by Country
3.7.1 Latin America Biological Vaccines Adjuvants Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Biological Vaccines Adjuvants Sales by Country (2018-2029)
3.7.3 Latin America Biological Vaccines Adjuvants Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biological Vaccines Adjuvants Market Facts & Figures by Country
3.8.1 Middle East and Africa Biological Vaccines Adjuvants Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Biological Vaccines Adjuvants Sales by Country (2018-2029)
3.8.3 Middle East and Africa Biological Vaccines Adjuvants Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biological Vaccines Adjuvants Sales by Type (2018-2029)
4.1.1 Global Biological Vaccines Adjuvants Sales by Type (2018-2024)
4.1.2 Global Biological Vaccines Adjuvants Sales by Type (2024-2029)
4.1.3 Global Biological Vaccines Adjuvants Sales Market Share by Type (2018-2029)
4.2 Global Biological Vaccines Adjuvants Revenue by Type (2018-2029)
4.2.1 Global Biological Vaccines Adjuvants Revenue by Type (2018-2024)
4.2.2 Global Biological Vaccines Adjuvants Revenue by Type (2024-2029)
4.2.3 Global Biological Vaccines Adjuvants Revenue Market Share by Type (2018-2029)
4.3 Global Biological Vaccines Adjuvants Price by Type (2018-2029)
5 Segment by Application
5.1 Global Biological Vaccines Adjuvants Sales by Application (2018-2029)
5.1.1 Global Biological Vaccines Adjuvants Sales by Application (2018-2024)
5.1.2 Global Biological Vaccines Adjuvants Sales by Application (2024-2029)
5.1.3 Global Biological Vaccines Adjuvants Sales Market Share by Application (2018-2029)
5.2 Global Biological Vaccines Adjuvants Revenue by Application (2018-2029)
5.2.1 Global Biological Vaccines Adjuvants Revenue by Application (2018-2024)
5.2.2 Global Biological Vaccines Adjuvants Revenue by Application (2024-2029)
5.2.3 Global Biological Vaccines Adjuvants Revenue Market Share by Application (2018-2029)
5.3 Global Biological Vaccines Adjuvants Price by Application (2018-2029)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.1.4 GSK Biological Vaccines Adjuvants Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Dynavax Technologies
6.2.1 Dynavax Technologies Corporation Information
6.2.2 Dynavax Technologies Description and Business Overview
6.2.3 Dynavax Technologies Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Dynavax Technologies Biological Vaccines Adjuvants Product Portfolio
6.2.5 Dynavax Technologies Recent Developments/Updates
6.3 Novavax
6.3.1 Novavax Corporation Information
6.3.2 Novavax Description and Business Overview
6.3.3 Novavax Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Novavax Biological Vaccines Adjuvants Product Portfolio
6.3.5 Novavax Recent Developments/Updates
6.4 Agenus
6.4.1 Agenus Corporation Information
6.4.2 Agenus Description and Business Overview
6.4.3 Agenus Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Agenus Biological Vaccines Adjuvants Product Portfolio
6.4.5 Agenus Recent Developments/Updates
6.5 Croda International
6.5.1 Croda International Corporation Information
6.5.2 Croda International Description and Business Overview
6.5.3 Croda International Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Croda International Biological Vaccines Adjuvants Product Portfolio
6.5.5 Croda International Recent Developments/Updates
6.6 Seppic
6.6.1 Seppic Corporation Information
6.6.2 Seppic Description and Business Overview
6.6.3 Seppic Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Seppic Biological Vaccines Adjuvants Product Portfolio
6.6.5 Seppic Recent Developments/Updates
6.7 OZ Biosciences
6.6.1 OZ Biosciences Corporation Information
6.6.2 OZ Biosciences Description and Business Overview
6.6.3 OZ Biosciences Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.4.4 OZ Biosciences Biological Vaccines Adjuvants Product Portfolio
6.7.5 OZ Biosciences Recent Developments/Updates
6.8 Phibro Animal Health Corporation
6.8.1 Phibro Animal Health Corporation Corporation Information
6.8.2 Phibro Animal Health Corporation Description and Business Overview
6.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Portfolio
6.8.5 Phibro Animal Health Corporation Recent Developments/Updates
6.9 Associated British Foods
6.9.1 Associated British Foods Corporation Information
6.9.2 Associated British Foods Description and Business Overview
6.9.3 Associated British Foods Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Associated British Foods Biological Vaccines Adjuvants Product Portfolio
6.9.5 Associated British Foods Recent Developments/Updates
6.10 InvivoGen
6.10.1 InvivoGen Corporation Information
6.10.2 InvivoGen Description and Business Overview
6.10.3 InvivoGen Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.10.4 InvivoGen Biological Vaccines Adjuvants Product Portfolio
6.10.5 InvivoGen Recent Developments/Updates
6.11 Merck KGaA
6.11.1 Merck KGaA Corporation Information
6.11.2 Merck KGaA Biological Vaccines Adjuvants Description and Business Overview
6.11.3 Merck KGaA Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Merck KGaA Biological Vaccines Adjuvants Product Portfolio
6.11.5 Merck KGaA Recent Developments/Updates
6.12 CSL Limited
6.12.1 CSL Limited Corporation Information
6.12.2 CSL Limited Biological Vaccines Adjuvants Description and Business Overview
6.12.3 CSL Limited Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.12.4 CSL Limited Biological Vaccines Adjuvants Product Portfolio
6.12.5 CSL Limited Recent Developments/Updates
6.13 Vertellus
6.13.1 Vertellus Corporation Information
6.13.2 Vertellus Biological Vaccines Adjuvants Description and Business Overview
6.13.3 Vertellus Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Vertellus Biological Vaccines Adjuvants Product Portfolio
6.13.5 Vertellus Recent Developments/Updates
6.14 Allergy Therapeutics
6.14.1 Allergy Therapeutics Corporation Information
6.14.2 Allergy Therapeutics Biological Vaccines Adjuvants Description and Business Overview
6.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Allergy Therapeutics Biological Vaccines Adjuvants Product Portfolio
6.14.5 Allergy Therapeutics Recent Developments/Updates
6.15 Riboxx GmbH
6.15.1 Riboxx GmbH Corporation Information
6.15.2 Riboxx GmbH Biological Vaccines Adjuvants Description and Business Overview
6.15.3 Riboxx GmbH Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Riboxx GmbH Biological Vaccines Adjuvants Product Portfolio
6.15.5 Riboxx GmbH Recent Developments/Updates
6.16 CaPtivatϵ Pharmaceuticals
6.16.1 CaPtivatϵ Pharmaceuticals Corporation Information
6.16.2 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Description and Business Overview
6.16.3 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.16.4 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product Portfolio
6.16.5 CaPtivatϵ Pharmaceuticals Recent Developments/Updates
6.17 EuBiologics
6.17.1 EuBiologics Corporation Information
6.17.2 EuBiologics Biological Vaccines Adjuvants Description and Business Overview
6.17.3 EuBiologics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.17.4 EuBiologics Biological Vaccines Adjuvants Product Portfolio
6.17.5 EuBiologics Recent Developments/Updates
6.18 Pacific GeneTech
6.18.1 Pacific GeneTech Corporation Information
6.18.2 Pacific GeneTech Biological Vaccines Adjuvants Description and Business Overview
6.18.3 Pacific GeneTech Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.18.4 Pacific GeneTech Biological Vaccines Adjuvants Product Portfolio
6.18.5 Pacific GeneTech Recent Developments/Updates
6.19 Hawaii Biotech
6.19.1 Hawaii Biotech Corporation Information
6.19.2 Hawaii Biotech Biological Vaccines Adjuvants Description and Business Overview
6.19.3 Hawaii Biotech Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.19.4 Hawaii Biotech Biological Vaccines Adjuvants Product Portfolio
6.19.5 Hawaii Biotech Recent Developments/Updates
6.20 Vaxine Pty Ltd.
6.20.1 Vaxine Pty Ltd. Corporation Information
6.20.2 Vaxine Pty Ltd. Biological Vaccines Adjuvants Description and Business Overview
6.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.20.4 Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Portfolio
6.20.5 Vaxine Pty Ltd. Recent Developments/Updates
6.21 Creative Diagnostics
6.21.1 Creative Diagnostics Corporation Information
6.21.2 Creative Diagnostics Biological Vaccines Adjuvants Description and Business Overview
6.21.3 Creative Diagnostics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.21.4 Creative Diagnostics Biological Vaccines Adjuvants Product Portfolio
6.21.5 Creative Diagnostics Recent Developments/Updates
6.22 LiteVax BV
6.22.1 LiteVax BV Corporation Information
6.22.2 LiteVax BV Biological Vaccines Adjuvants Description and Business Overview
6.22.3 LiteVax BV Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.22.4 LiteVax BV Biological Vaccines Adjuvants Product Portfolio
6.22.5 LiteVax BV Recent Developments/Updates
6.23 Mukta Industries
6.23.1 Mukta Industries Corporation Information
6.23.2 Mukta Industries Biological Vaccines Adjuvants Description and Business Overview
6.23.3 Mukta Industries Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.23.4 Mukta Industries Biological Vaccines Adjuvants Product Portfolio
6.23.5 Mukta Industries Recent Developments/Updates
6.24 Oncovir
6.24.1 Oncovir Corporation Information
6.24.2 Oncovir Biological Vaccines Adjuvants Description and Business Overview
6.24.3 Oncovir Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.24.4 Oncovir Biological Vaccines Adjuvants Product Portfolio
6.24.5 Oncovir Recent Developments/Updates
6.25 TiterMax USA
6.25.1 TiterMax USA Corporation Information
6.25.2 TiterMax USA Biological Vaccines Adjuvants Description and Business Overview
6.25.3 TiterMax USA Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2018-2024)
6.25.4 TiterMax USA Biological Vaccines Adjuvants Product Portfolio
6.25.5 TiterMax USA Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biological Vaccines Adjuvants Industry Chain Analysis
7.2 Biological Vaccines Adjuvants Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biological Vaccines Adjuvants Production Mode & Process
7.4 Biological Vaccines Adjuvants Sales and Marketing
7.4.1 Biological Vaccines Adjuvants Sales Channels
7.4.2 Biological Vaccines Adjuvants Distributors
7.5 Biological Vaccines Adjuvants Customers
8 Biological Vaccines Adjuvants Market Dynamics
8.1 Biological Vaccines Adjuvants Industry Trends
8.2 Biological Vaccines Adjuvants Market Drivers
8.3 Biological Vaccines Adjuvants Market Challenges
8.4 Biological Vaccines Adjuvants Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Biological Vaccines Adjuvants Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Biological Vaccines Adjuvants Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Biological Vaccines Adjuvants Market Competitive Situation by Manufacturers in 2022
Table 4. Global Biological Vaccines Adjuvants Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Biological Vaccines Adjuvants Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Biological Vaccines Adjuvants Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Biological Vaccines Adjuvants Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Biological Vaccines Adjuvants, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Biological Vaccines Adjuvants, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biological Vaccines Adjuvants, Product Type & Application
Table 12. Global Key Manufacturers of Biological Vaccines Adjuvants, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biological Vaccines Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Vaccines Adjuvants as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biological Vaccines Adjuvants Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Biological Vaccines Adjuvants Sales by Region (2018-2024) & (K Units)
Table 18. Global Biological Vaccines Adjuvants Sales Market Share by Region (2018-2024)
Table 19. Global Biological Vaccines Adjuvants Sales by Region (2024-2029) & (K Units)
Table 20. Global Biological Vaccines Adjuvants Sales Market Share by Region (2024-2029)
Table 21. Global Biological Vaccines Adjuvants Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Biological Vaccines Adjuvants Revenue Market Share by Region (2018-2024)
Table 23. Global Biological Vaccines Adjuvants Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Biological Vaccines Adjuvants Revenue Market Share by Region (2024-2029)
Table 25. North America Biological Vaccines Adjuvants Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Biological Vaccines Adjuvants Sales by Country (2018-2024) & (K Units)
Table 27. North America Biological Vaccines Adjuvants Sales by Country (2024-2029) & (K Units)
Table 28. North America Biological Vaccines Adjuvants Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Biological Vaccines Adjuvants Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Biological Vaccines Adjuvants Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Biological Vaccines Adjuvants Sales by Country (2018-2024) & (K Units)
Table 32. Europe Biological Vaccines Adjuvants Sales by Country (2024-2029) & (K Units)
Table 33. Europe Biological Vaccines Adjuvants Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Biological Vaccines Adjuvants Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Biological Vaccines Adjuvants Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Biological Vaccines Adjuvants Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Biological Vaccines Adjuvants Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Biological Vaccines Adjuvants Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Biological Vaccines Adjuvants Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Biological Vaccines Adjuvants Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Biological Vaccines Adjuvants Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Biological Vaccines Adjuvants Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Biological Vaccines Adjuvants Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Biological Vaccines Adjuvants Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Biological Vaccines Adjuvants Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Biological Vaccines Adjuvants Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Biological Vaccines Adjuvants Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Biological Vaccines Adjuvants Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Biological Vaccines Adjuvants Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Biological Vaccines Adjuvants Sales (K Units) by Type (2018-2024)
Table 51. Global Biological Vaccines Adjuvants Sales (K Units) by Type (2024-2029)
Table 52. Global Biological Vaccines Adjuvants Sales Market Share by Type (2018-2024)
Table 53. Global Biological Vaccines Adjuvants Sales Market Share by Type (2024-2029)
Table 54. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Biological Vaccines Adjuvants Revenue Market Share by Type (2018-2024)
Table 57. Global Biological Vaccines Adjuvants Revenue Market Share by Type (2024-2029)
Table 58. Global Biological Vaccines Adjuvants Price (US$/Unit) by Type (2018-2024)
Table 59. Global Biological Vaccines Adjuvants Price (US$/Unit) by Type (2024-2029)
Table 60. Global Biological Vaccines Adjuvants Sales (K Units) by Application (2018-2024)
Table 61. Global Biological Vaccines Adjuvants Sales (K Units) by Application (2024-2029)
Table 62. Global Biological Vaccines Adjuvants Sales Market Share by Application (2018-2024)
Table 63. Global Biological Vaccines Adjuvants Sales Market Share by Application (2024-2029)
Table 64. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Biological Vaccines Adjuvants Revenue Market Share by Application (2018-2024)
Table 67. Global Biological Vaccines Adjuvants Revenue Market Share by Application (2024-2029)
Table 68. Global Biological Vaccines Adjuvants Price (US$/Unit) by Application (2018-2024)
Table 69. Global Biological Vaccines Adjuvants Price (US$/Unit) by Application (2024-2029)
Table 70. GSK Corporation Information
Table 71. GSK Description and Business Overview
Table 72. GSK Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. GSK Biological Vaccines Adjuvants Product
Table 74. GSK Recent Developments/Updates
Table 75. Dynavax Technologies Corporation Information
Table 76. Dynavax Technologies Description and Business Overview
Table 77. Dynavax Technologies Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Dynavax Technologies Biological Vaccines Adjuvants Product
Table 79. Dynavax Technologies Recent Developments/Updates
Table 80. Novavax Corporation Information
Table 81. Novavax Description and Business Overview
Table 82. Novavax Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Novavax Biological Vaccines Adjuvants Product
Table 84. Novavax Recent Developments/Updates
Table 85. Agenus Corporation Information
Table 86. Agenus Description and Business Overview
Table 87. Agenus Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Agenus Biological Vaccines Adjuvants Product
Table 89. Agenus Recent Developments/Updates
Table 90. Croda International Corporation Information
Table 91. Croda International Description and Business Overview
Table 92. Croda International Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Croda International Biological Vaccines Adjuvants Product
Table 94. Croda International Recent Developments/Updates
Table 95. Seppic Corporation Information
Table 96. Seppic Description and Business Overview
Table 97. Seppic Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Seppic Biological Vaccines Adjuvants Product
Table 99. Seppic Recent Developments/Updates
Table 100. OZ Biosciences Corporation Information
Table 101. OZ Biosciences Description and Business Overview
Table 102. OZ Biosciences Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. OZ Biosciences Biological Vaccines Adjuvants Product
Table 104. OZ Biosciences Recent Developments/Updates
Table 105. Phibro Animal Health Corporation Corporation Information
Table 106. Phibro Animal Health Corporation Description and Business Overview
Table 107. Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Phibro Animal Health Corporation Biological Vaccines Adjuvants Product
Table 109. Phibro Animal Health Corporation Recent Developments/Updates
Table 110. Associated British Foods Corporation Information
Table 111. Associated British Foods Description and Business Overview
Table 112. Associated British Foods Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Associated British Foods Biological Vaccines Adjuvants Product
Table 114. Associated British Foods Recent Developments/Updates
Table 115. InvivoGen Corporation Information
Table 116. InvivoGen Description and Business Overview
Table 117. InvivoGen Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. InvivoGen Biological Vaccines Adjuvants Product
Table 119. InvivoGen Recent Developments/Updates
Table 120. Merck KGaA Corporation Information
Table 121. Merck KGaA Description and Business Overview
Table 122. Merck KGaA Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Merck KGaA Biological Vaccines Adjuvants Product
Table 124. Merck KGaA Recent Developments/Updates
Table 125. CSL Limited Corporation Information
Table 126. CSL Limited Description and Business Overview
Table 127. CSL Limited Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. CSL Limited Biological Vaccines Adjuvants Product
Table 129. CSL Limited Recent Developments/Updates
Table 130. Vertellus Corporation Information
Table 131. Vertellus Description and Business Overview
Table 132. Vertellus Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Vertellus Biological Vaccines Adjuvants Product
Table 134. Vertellus Recent Developments/Updates
Table 135. Allergy Therapeutics Corporation Information
Table 136. Allergy Therapeutics Description and Business Overview
Table 137. Allergy Therapeutics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Allergy Therapeutics Biological Vaccines Adjuvants Product
Table 139. Allergy Therapeutics Recent Developments/Updates
Table 140. Riboxx GmbH Corporation Information
Table 141. Riboxx GmbH Description and Business Overview
Table 142. Riboxx GmbH Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. Riboxx GmbH Biological Vaccines Adjuvants Product
Table 144. Riboxx GmbH Recent Developments/Updates
Table 145. CaPtivatϵ Pharmaceuticals Corporation Information
Table 146. CaPtivatϵ Pharmaceuticals Description and Business Overview
Table 147. CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 148. CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product
Table 149. CaPtivatϵ Pharmaceuticals Recent Developments/Updates
Table 150. EuBiologics Corporation Information
Table 151. EuBiologics Description and Business Overview
Table 152. EuBiologics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 153. EuBiologics Biological Vaccines Adjuvants Product
Table 154. EuBiologics Recent Developments/Updates
Table 155. Pacific GeneTech Corporation Information
Table 156. Pacific GeneTech Description and Business Overview
Table 157. Pacific GeneTech Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 158. Pacific GeneTech Biological Vaccines Adjuvants Product
Table 159. Pacific GeneTech Recent Developments/Updates
Table 160. Hawaii Biotech Corporation Information
Table 161. Hawaii Biotech Description and Business Overview
Table 162. Hawaii Biotech Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 163. Hawaii Biotech Biological Vaccines Adjuvants Product
Table 164. Hawaii Biotech Recent Developments/Updates
Table 165. Vaxine Pty Ltd. Corporation Information
Table 166. Vaxine Pty Ltd. Description and Business Overview
Table 167. Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 168. Vaxine Pty Ltd. Biological Vaccines Adjuvants Product
Table 169. Vaxine Pty Ltd. Recent Developments/Updates
Table 170. Creative Diagnostics Corporation Information
Table 171. Creative Diagnostics Description and Business Overview
Table 172. Creative Diagnostics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 173. Creative Diagnostics Biological Vaccines Adjuvants Product
Table 174. Creative Diagnostics Recent Developments/Updates
Table 175. LiteVax BV Corporation Information
Table 176. LiteVax BV Description and Business Overview
Table 177. LiteVax BV Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 178. LiteVax BV Biological Vaccines Adjuvants Product
Table 179. LiteVax BV Recent Developments/Updates
Table 180. Mukta Industries Corporation Information
Table 181. Mukta Industries Description and Business Overview
Table 182. Mukta Industries Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 183. Mukta Industries Biological Vaccines Adjuvants Product
Table 184. Mukta Industries Recent Developments/Updates
Table 185. Oncovir Corporation Information
Table 186. Oncovir Description and Business Overview
Table 187. Oncovir Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 188. Oncovir Biological Vaccines Adjuvants Product
Table 189. Oncovir Recent Developments/Updates
Table 190. TiterMax USA Corporation Information
Table 191. TiterMax USA Description and Business Overview
Table 192. TiterMax USA Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 193. TiterMax USA Biological Vaccines Adjuvants Product
Table 194. TiterMax USA Recent Developments/Updates
Table 195. Key Raw Materials Lists
Table 196. Raw Materials Key Suppliers Lists
Table 197. Biological Vaccines Adjuvants Distributors List
Table 198. Biological Vaccines Adjuvants Customers List
Table 199. Biological Vaccines Adjuvants Market Trends
Table 200. Biological Vaccines Adjuvants Market Drivers
Table 201. Biological Vaccines Adjuvants Market Challenges
Table 202. Biological Vaccines Adjuvants Market Restraints
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biological Vaccines Adjuvants
Figure 2. Global Biological Vaccines Adjuvants Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Biological Vaccines Adjuvants Market Share by Type in 2022 & 2029
Figure 4. Aluminum Adjuvant Product Picture
Figure 5. Emulsions Adjuvant Product Picture
Figure 6. Others Product Picture
Figure 7. Global Biological Vaccines Adjuvants Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Biological Vaccines Adjuvants Market Share by Application in 2022 & 2029
Figure 9. Human Vaccine
Figure 10. Veterinary Vaccine
Figure 11. Global Biological Vaccines Adjuvants Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Biological Vaccines Adjuvants Market Size (2018-2029) & (US$ Million)
Figure 13. Global Biological Vaccines Adjuvants Sales (2018-2029) & (K Units)
Figure 14. Global Biological Vaccines Adjuvants Average Price (US$/Unit) & (2018-2029)
Figure 15. Biological Vaccines Adjuvants Report Years Considered
Figure 16. Biological Vaccines Adjuvants Sales Share by Manufacturers in 2022
Figure 17. Global Biological Vaccines Adjuvants Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Biological Vaccines Adjuvants Players: Market Share by Revenue in 2022
Figure 19. Biological Vaccines Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Biological Vaccines Adjuvants Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Biological Vaccines Adjuvants Sales Market Share by Country (2018-2029)
Figure 22. North America Biological Vaccines Adjuvants Revenue Market Share by Country (2018-2029)
Figure 23. United States Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Biological Vaccines Adjuvants Sales Market Share by Country (2018-2029)
Figure 26. Europe Biological Vaccines Adjuvants Revenue Market Share by Country (2018-2029)
Figure 27. Germany Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Biological Vaccines Adjuvants Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Biological Vaccines Adjuvants Revenue Market Share by Region (2018-2029)
Figure 34. China Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. China Taiwan Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Biological Vaccines Adjuvants Sales Market Share by Country (2018-2029)
Figure 44. Latin America Biological Vaccines Adjuvants Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Biological Vaccines Adjuvants Sales Market Share by Country (2018-2029)
Figure 49. Middle East & Africa Biological Vaccines Adjuvants Revenue Market Share by Country (2018-2029)
Figure 50. Turkey Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. UAE Biological Vaccines Adjuvants Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Global Sales Market Share of Biological Vaccines Adjuvants by Type (2018-2029)
Figure 54. Global Revenue Market Share of Biological Vaccines Adjuvants by Type (2018-2029)
Figure 55. Global Biological Vaccines Adjuvants Price (US$/Unit) by Type (2018-2029)
Figure 56. Global Sales Market Share of Biological Vaccines Adjuvants by Application (2018-2029)
Figure 57. Global Revenue Market Share of Biological Vaccines Adjuvants by Application (2018-2029)
Figure 58. Global Biological Vaccines Adjuvants Price (US$/Unit) by Application (2018-2029)
Figure 59. Biological Vaccines Adjuvants Value Chain
Figure 60. Biological Vaccines Adjuvants Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed